ConSynance Therapeutics Announces U.S. FDA Grants Rare Pediatric Disease Designation to CSTI-500, a Potential First-in-Class Therapy for Prader-Willi Syndrome
24 juil. 2024 10h00 HE
|
ConSynance Therapeutics
FDA awards ConSynance's CSTI-500 Rare Pediatric Disease Designation for innovative Prader-Willi Syndrome treatment.
YPrime Launches Breakthrough eCOA Platform to Deliver Up to 30% Faster Implementations
24 juil. 2024 09h00 HE
|
Y-Prime, LLC
YPrime releases groundbreaking eCOA platform to revolutionize the clinical trial landscape.
ImmunOs Therapeutics Expands Phase I Clinical Trial of IOS-1002 in Combination with KEYTRUDA® (pembrolizumab) for the Treatment of Solid Tumors
24 juil. 2024 04h00 HE
|
AKAMPION
Dosing of patients in new combination treatment arm – IOS-1002 plus KEYTRUDA Schlieren (Zurich Area), Switzerland – July 24, 2024 – ImmunOs Therapeutics AG, a biopharmaceutical company using its...
60 Degrees Pharmaceuticals Signs Clinical Trial Agreements With All Planned Trial Sites for Tafenoquine Babesiosis Study
19 juil. 2024 08h29 HE
|
Sixty Degrees Pharmaceuticals
60 Degrees Pharma begins enrolling patients for a tafenoquine babesiosis trial at Yale, Tufts, and Rhode Island Hospital, with results expected Sept., 2025
Biora Therapeutics Announces Supplemental Data from Phase 1 Clinical Trial of BT-600 as Presented at KOL Event
18 juil. 2024 08h00 HE
|
Biora Therapeutics, Inc.
Pharmacokinetic and tissue data confirm NaviCap platform delivers topically through the entire colon, with lower systemic concentrations, as desired.
First patient dosed in Phase 3 Gliofocus Study for newly diagnosed glioblastoma patients at the Ivy Brain Tumor Center
17 juil. 2024 08h00 HE
|
Ivy Brain Tumor Center
Phoenix, AZ, July 17, 2024 (GLOBE NEWSWIRE) -- Gliofocus is a global, registrational, randomized, controlled Phase 3 clinical trial comparing niraparib vs temozolomide in newly diagnosed...
Sabin Vaccine Institute Begins Phase 2 Clinical Trial for Sudan Ebolavirus Vaccine
15 juil. 2024 10h29 HE
|
Sabin Vaccine Institute
Laboratory at Makerere University Walter Reed Project, where Sabin’s Phase 2 Sudan ebolavirus vaccine clinical trial begins this month. WASHINGTON, July 15, 2024 (GLOBE NEWSWIRE) -- Sabin Vaccine...
OKYO Pharma to Initiate Neuropathic Corneal Pain Trial for OK-101
11 juil. 2024 07h00 HE
|
OKYO Pharma LTD
Phase 2 randomized, placebo-controlled trial in neuropathic corneal pain (NCP) patients planned to begin in Q3, 2024OK-101 is believed to be the first IND clearance granted by FDA for a drug to begin...
Aviv Clinics Spotlights New Study Sharing Further Evidence That Specific Hyperbaric Oxygen Therapy is Effective in Fighting Aging
09 juil. 2024 09h00 HE
|
Aviv Clinics
ORLANDO, Fla., July 09, 2024 (GLOBE NEWSWIRE) -- Aviv Clinics, one of the most advanced brain clinics in the world, shares the results of a new study showing a unique hyperbaric oxygen therapy...
Athira Pharma Announces Last Patient Completed LIFT-AD Clinical Trial of Fosgonimeton in Mild-to-Moderate Alzheimer’s Disease
09 juil. 2024 07h00 HE
|
Athira Pharma, Inc.
Athira Pharma Announces Last Patient Completed LIFT-AD Clinical Trial of Fosgonimeton in Mild-to-Moderate Alzheimer’s Disease